Activation of coagulation by a thalidomide-based regimen

Blood Coagulation and Fibrinolysis

Volumn 22, Issue 6, 2011, Pages 532-540

  Hoshi, Asuka ^a   Matsumoto, Aya ^a   Chung, Jihwa ^a   Isozumi, Yu ^a   Koyama, Takatoshi ^a  

^a TOKYO MEDICAL AND DENTAL UNIVERSITY   (Japan)

Author keywords

dexamethasone; doxorubicin; phosphatidylserine; thalidomide; tissue factor

Indexed keywords

DEXAMETHASONE; DOXORUBICIN; LIPOCORTIN 5; PHOSPHATIDYLSERINE; THALIDOMIDE; THROMBOPLASTIN;

ARTICLE; BLOOD CLOTTING; CONTROLLED STUDY; DRUG MECHANISM; ENDOTHELIUM CELL; HUMAN; HUMAN CELL; IN VITRO STUDY; MONOCYTE; MYELOMA CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; UPREGULATION;

ANNEXIN A5; ANTICOAGULANTS; ANTINEOPLASTIC AGENTS; BLOOD COAGULATION; BLOOD COAGULATION FACTORS; CELL LINE; DEXAMETHASONE; DOXORUBICIN; DRUG COMBINATIONS; DRUG INTERACTIONS; ENDOTHELIAL CELLS; ENDOTHELIUM, VASCULAR; FLOW CYTOMETRY; HUMANS; MONOCYTES; MULTIPLE MYELOMA; PHOSPHATIDYLSERINES; THALIDOMIDE; THROMBOPLASTIN; VENOUS THROMBOSIS;

EID: 80052079465     PISSN: 09575235     EISSN: 14735733     Source Type: Journal    
DOI: 10.1097/MBC.0b013e328348629d     Document Type: Article

References (36)

1. Kumar SK, Rajkumar SV, Dispenzieri A, Lacy MQ, Hayman SR, Buadi FK, et al. Improved survival in multiple myeloma and the impact of novel therapies. Blood 2008; 111:2516-2520.
2. Cavo M, Zamagni E, Tosi P, Cellini C, Cangini D, Tacchetti P, et al. First-line therapy with thalidomide and dexamethasone in preparation for autologous stem cell transplantation for multiple myeloma. Haematologica 2004; 89:826-831. (Pubitemid 38981342)
3. Zangari M, Barlogie B, Anaissie E, Saghafifar F, Eddlemon P, Jacobson J, et al. Deep vein thrombosis in patients with multiple myeloma treated with thalidomide and chemotherapy: effects of prophylactic and therapeutic anticoagulation. Br J Haematol 2004; 126:715-721. (Pubitemid 39221309)
4. Baz R, Li L, Kottke-Marchant K, Srkalovic G, McGowan B, Yiannaki E, et al. The role of aspirin in the prevention of thrombotic complications of thalidomide and anthracycline-based chemotherapy for multiple myeloma. Mayo Clin Proc 2005; 80:1568-1574. (Pubitemid 41747058)
5. Palumbo A, Bringhen S, Caravita T, Merla E, Capparella V, Callea V, et al. Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: randomised controlled trial. Lancet 2006; 367:825-831. (Pubitemid 43363369)
6. El Accaoui RN, Shamseddeen WA, Taher AT. Thalidomide and thrombosis. A meta-analysis. Thromb Haemost 2007; 97:1031-1036.
7. Bach RR. Tissue factor encryption. Arterioscler Thromb Vasc Biol 2006; 26:456-461.
8. Mackman N. Regulation of the tissue factor gene. Thromb Haemost 1997; 78:747-754.
9. Morrissey JH, Pureza V, Davis-Harrison RL, Sligar SG, Rienstra CM, Kijac AZ, et al. Protein-membrane interactions: blood clotting on nanoscale bilayers. J Thromb Haemost 2009; 7 (Suppl 1):169-172.
10. Zangari M, Siegel E, Barlogie B, Anaissie E, Saghafifar F, Fassas A, et al. Thrombogenic activity of doxorubicin in myeloma patients receiving thalidomide: implications for therapy. Blood 2002; 100:1168-1171. (Pubitemid 34864267)
11. Chung J, Suzuki H, Tabuchi N, Sato K, Shibamiya A, Koyama T. Identification of tissue factor and platelet-derived particles on leukocytes during cardiopulmonary bypass by flow cytometry and immunoelectron microscopy. Thromb Haemost 2007; 98:368-374. (Pubitemid 47250240)
12. Shibamiya A, Tabuchi N, Chung J, Sunamori M, Koyama T. Formation of tissue factor-bearing leukocytes during and after cardiopulmonary bypass. Thromb Haemost 2004; 92:124-131. (Pubitemid 39010875)
13. 3 blocks TNF-induced monocytic tissue factor expression by inhibition of transcription factors AP-1 and NF-kB. Lab Invest 2007; 87:540-547. (Pubitemid 46788792)
14. Palumbo A, Rajkumar SV, Dimopoulos MA, Richardson PG, San Miguel J, Barlogie B, et al. Prevention of thalidomide-and lenalidomide-associated thrombosis in myeloma. Leukemia 2008; 22:414-423. (Pubitemid 351255436)
15. Rajkumar SV, Hayman S, Gertz MA, Dispenzieri A, Lacy MQ, Greipp PR, et al. Combination therapy with thalidomide plus dexamethasone for newly diagnosed myeloma. J Clin Oncol 2002; 20:4319-4323. (Pubitemid 35266292)
16. Rajkumar SV, Blood E, Vesole D, Fonseca R, Greipp PR. Phase III clinical trial of thalidomide plus dexamethasone compared with dexamethasone alone in newly diagnosed multiple myeloma: a clinical trial coordinated by the Eastern Cooperative Oncology Group. J Clin Oncol 2006; 24:431-436. (Pubitemid 46630462)
17. Anagnostopoulos A, Weber D, Rankin K, Delasalle K, Alexanian R. Thalidomide and dexamethasone for resistant multiple myeloma. Br J Haematol 2003; 121:768-771. (Pubitemid 36718193)
18. Palumbo A, Bertola A, Falco P, Rosato R, Cavallo F, Giaccone L, et al. Efficacy of low-dose thalidomide and dexamethasone as first salvage regimen in multiple myeloma. Hematol J 2004; 5:318-324. (Pubitemid 39214209)
19. Osman K, Comenzo R, Rajkumar SV. Deep venous thrombosis and thalidomide therapy for multiple myeloma. N Engl J Med 2001; 344:1951-1952. (Pubitemid 32553371)
20. Zervas K, Dimopoulos MA, Hatzicharissi E, Anagnostopoulos A, Papaioannou M, Mitsouli C, et al. Primary treatment of multiple myeloma with thalidomide, vincristine, liposomal doxorubicin and dexamethasone (T-VAD doxil): a phase II multicenter study. Ann Oncol 2004; 15:134-138. (Pubitemid 38139615)
21. Bombeli T, Karsan A, Tait JF, Harlan JM. Apoptotic vascular endothelial cells become procoagulant. Blood 1997; 89:2429-2442. (Pubitemid 27143290)
22. Lorenzo E, Ruiz-Ruiz C, Quesada AJ, Hernandez G, Rodriguez A, Lopez-Rivas A, etal. Doxorubicin induces apoptosis and CD95 gene expression in human primary endothelial cells through a p53-dependent mechanism. J Biol Chem 2002; 277:10883-10892. (Pubitemid 34952843)
23. Fu Y, Zhou J, Li H, Cao F, Su Y, Fan S, et al. Daunorubicin induces procoagulant activity of cultured endothelial cells through phosphatidylserine exposure and microparticles release. Thromb Haemost 2010; 104:1235-1241.
24. George FD. Microparticles in vascular diseases. Thromb Res 2008; 122 (Suppl 1):S55-S59.
25. Lechner D, Kollars M, Gleiss A, Kyrle PA, Weltermann A. Chemotherapy-induced thrombin generation via procoagulant endothelial microparticles is independent of tissue factor activity. J Thromb Haemost 2007; 5:2445-2452. (Pubitemid 350154355)
26. Valsami S, Ruf W, Leikauf MS, Madon J, Kaech A, Asmis LM. Immunomodulatory drugs increase endothelial tissue factor expression in vitro. Thromb Res 2011; 127:264-271.
27. Raza A, Mehdi M, Mumtaz M, Ali F, Lascher S, Galili N. Combination of 5-azacytidine and thalidomide for the treatment of myelodysplastic syndromes and acute myeloid leukemia. Cancer 2008; 113:1596-1604.
28. Steurer M, Sudmeier I, Stauder R, Gastl G. Thromboembolic events in patients with myelodysplastic syndrome receiving thalidomide in combination with darbepoietin-alpha. Br J Haematol 2003; 121:101-103. (Pubitemid 36461274)
29. Weber D, Rankin K, Gavino M, Delasalle K, Alexanian R. Thalidomide alone or with dexamethasone for previously untreated multiple myeloma. J Clin Oncol 2003; 21:16-19.
30. Shyu VB-h, Wang P-N, Chu P-H. Low incidence of venous thromboembolism in Asian myeloma patients treated with thalidomide plus dexamethasone. Asia Pac J Oncol Hematol 2010; 2:41-47.
31. Zonder JA, Barlogie B, Durie BG, McCoy J, Crowley J, Hussein MA. Thrombotic complications in patients with newly diagnosed multiple myeloma treated with lenalidomide and dexamethasone: benefit of aspirin prophylaxis. Blood 2006; 108:403; Author reply 404. (Pubitemid 43990659)
32. Weber DM, Chen C, Niesvizky R, Wang M, Belch A, Stadtmauer EA, et al. Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America. N Engl J Med 2007; 357:2133-2142. (Pubitemid 350146108)
33. Dimopoulos M, Spencer A, Attal M, Prince HM, Harousseau JL, Dmoszynska A, et al. Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma. N Engl J Med 2007; 357:2123-2132. (Pubitemid 350146107)
34. Geerts WH, Bergqvist D, Pineo GF, Heit JA, Samama CM, Lassen MR, et al. Prevention of venous thromboembolism: American College of Chest Physicians Evidence-based clinical practice guidelines (8th edition). Chest 2008; 133 (6 Suppl):381S-453S. (Pubitemid 351894916)
35. Laux V, Perzborn E, Heitmeier S, von Degenfeld G, Dittrich-Wengenroth E, Buchmuller A, et al. Direct inhibitors of coagulation proteins: the end of the heparin and low-molecular-weight heparin era for anticoagulant therapy? Thromb Haemost 2009; 102:892-899.
36. Zangari M, Tricot G, Polavaram L, Zhan F, Finlayson A, Knight R, et al. Survival effect of venous thromboembolism in patients with multiple myeloma treated with lenalidomide and high-dose dexamethasone. J Clin Oncol 2010; 28:132-135.